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BACKGROUND
Patients with noninfectious uveitis are at risk for long-term complications of uncon-
trolled inflammation, as well as for the adverse effects of long-term glucocorticoid 
therapy. We conducted a trial to assess the efficacy and safety of adalimumab as a 
glucocorticoid-sparing agent for the treatment of noninfectious uveitis.
METHODS
This multinational phase 3 trial involved adults who had active noninfectious interme-
diate uveitis, posterior uveitis, or panuveitis despite having received prednisone treat-
ment for 2 or more weeks. Investigators and patients were unaware of the study-group 
assignments. Patients were randomly assigned in a 1:1 ratio to receive adalimumab 
(a loading dose of 80 mg followed by a dose of 40 mg every 2 weeks) or matched 
placebo. All patients received a mandatory prednisone burst followed by tapering of 
prednisone over the course of 15 weeks. The primary efficacy end point was the time 
to treatment failure occurring at or after week 6. Treatment failure was a multicom-
ponent outcome that was based on assessment of new inflammatory lesions, best 
corrected visual acuity, anterior chamber cell grade, and vitreous haze grade. Nine 
ranked secondary efficacy end points were assessed, and adverse events were reported.
RESULTS
The median time to treatment failure was 24 weeks in the adalimumab group and 13 
weeks in the placebo group. Among the 217 patients in the intention-to-treat popula-
tion, those receiving adalimumab were less likely than those in the placebo group to 
have treatment failure (hazard ratio, 0.50; 95% confidence interval, 0.36 to 0.70; 
P<0.001). Outcomes with regard to three secondary end points (change in anterior 
chamber cell grade, change in vitreous haze grade, and change in best corrected vi-
sual acuity) were significantly better in the adalimumab group than in the placebo 
group. Adverse events and serious adverse events were reported more frequently 
among patients who received adalimumab (1052.4 vs. 971.7 adverse events and 28.8 
vs. 13.6 serious adverse events per 100 person-years).
CONCLUSIONS
In our trial, adalimumab was found to be associated with a lower risk of uveitic flare 
or visual impairment and with more adverse events and serious adverse events than 
was placebo. (Funded by AbbVie; VISUAL I ClinicalTrials.gov number, NCT01138657.)
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Noninfectious uveitis is a group of vision-threatening diseases that are characterized by intraocular inflamma-
tion; it can occur as a syndrome isolated to the 
eye or in association with a systemic condition. 
Uveitis has an estimated incidence of 17 to 52 
cases per 100,000 person-years1 and is estimated 
to cause 10 to 15% of cases of blindness in 
Western countries.2,3 Glucocorticoids remain the 
mainstay of therapy despite their well-known 
ocular and systemic adverse effects.4-6 Thus, 
there is a large unmet medical need for and a 
great interest in identifying more effective, gluco-
corticoid-sparing therapies, ideally targeting spe-
cific mediators of the immune response.4,5,7,8
The proinflammatory cytokine tumor necro-
sis factor α (TNF-α) is thought to play a key role 
in uveitic inflammation,9,10 and aqueous humor 
and serum levels of TNF-α are up-regulated in 
patients with uveitis.11 Adalimumab, a fully hu-
man anti–TNF-α monoclonal antibody, is indi-
cated for several inflammatory conditions that 
may be associated with intraocular inflamma-
tion.12 Uncontrolled case series, retrospective 
chart reviews, and small open-label studies have 
suggested that adalimumab is effective in treat-
ing patients with chronic or refractory uveitis 
and in reducing glucocorticoid use.13-19
To evaluate the efficacy and safety of an anti–
TNF-α drug in patients with active, noninfectious 
uveitis, we conducted a multicenter, randomized, 
placebo-controlled trial in which patients and 
investigators were unaware of the study-group 
assignments. The objective was to assess the 
efficacy of adalimumab as a glucocorticoid-
sparing agent for the control of uveitis.
Me thods
Trial Design and Oversight
We performed this phase 3 trial in 18 countries 
from August 2010 through August 2014. The 
trial protocol was approved by an independent 
ethics committee or institutional review board at 
each study site, and the trial was performed in 
compliance with the provisions of the Declara-
tion of Helsinki, International Conference on 
Harmonisation Good Clinical Practice guidelines, 
and applicable local regulations. Patients pro-
vided written informed consent at enrollment. 
The trial was designed jointly by the investiga-
tors and the sponsor (AbbVie). The investigators 
collected the data, and the sponsor conducted 
the data analyses. All the authors had full access 
to the data; there was an agreement between the 
investigators and the sponsor not to disclose any 
trial information that was not publicly available. 
The first draft of the manuscript was written by 
a medical writer (paid with funds from the 
sponsor), with input from all the authors. All the 
authors reviewed and provided feedback on all 
subsequent manuscript drafts and made the de-
cision to submit the manuscript for publication; 
the sponsor also reviewed and approved the 
manuscript. All the authors vouch for the com-
pleteness and accuracy of the data and analyses 
and affirm that the trial was conducted and re-
ported with fidelity to the protocol, available 
with the full text of this article at NEJM.org. 
A small substudy involving 16 Japanese patients 
was conducted separately, as planned, because of 
the potential for regional heterogeneity; the re-
sults of the substudy are not reported here.
Trial Participants
Patients who were 18 years of age or older and 
had a diagnosis of active noninfectious interme-
diate uveitis, posterior uveitis, or panuveitis were 
eligible to participate in the trial. The key inclu-
sion criteria were active disease characterized 
by at least one active inflammatory chorioretinal 
or retinal vascular lesion, anterior chamber cell 
grade of 2+ or higher (according to Standardiza-
tion of Uveitis Nomenclature Working Group 
criteria; scores range from 0 to 4+, with higher 
scores indicating more cells visible in the ante-
rior chamber and greater severity of uveitis),20 or 
vitreous haze grade of 2+ or higher (according 
to National Eye Institute [NEI] criteria adapted 
by the Standardization of Uveitis Nomenclature 
Working Group; scores range from 0 to 4+, with 
higher scores indicating greater severity of uve-
itis)20,21 despite the use of prednisone (10 to 60 mg 
per day) or an equivalent glucocorticoid for 2 or 
more weeks before screening. The full inclusion 
and exclusion criteria are provided in Table S1 
in the Supplementary Appendix, available at 
NEJM.org. For all patients, both eyes were eli-
gible for analysis.
Randomization and Treatment
At the baseline visit, patients were randomly as-
signed in a 1:1 ratio to the adalimumab group or 
the placebo group, with stratification according 
to baseline immunosuppressant treatment; ran-
domization was performed with the use of a 
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random assignment sequence that was computer-
generated in the AbbVie statistics department. 
An interactive voice-response or Web-response 
system was used to assign each patient a number 
and group.
Adalimumab and matched placebo were sup-
plied in prefilled syringes and were adminis-
tered subcutaneously. Patients in the adalimumab 
group received an 80-mg dose at baseline fol-
lowed by 40-mg doses every 2 weeks starting 
at week 1 and continuing for the duration of 
the trial. All patients received a standardized, 
60-mg-per-day prednisone burst at trial entry 
(week 0), after which a mandatory tapering 
schedule was followed (Table S2 in the Supple-
mentary Appendix). All patients had discontin-
ued prednisone treatment by week 15.
Study Visits and End Points
Clinic visits were scheduled to occur at screen-
ing; at baseline; at weeks 1, 4, 6, and 8; and 
approximately every 4 weeks thereafter. Patients’ 
conditions were evaluated until the determina-
tion of treatment failure or the completion of 
80 weeks of treatment. The trial was ended 
when a prespecified number of treatment-failure 
events — 138 events, as defined below — were 
recorded (144 actual treatment failures were in-
cluded, because six patients had treatment fail-
ure during the patient rollout period, which was 
the time after 138 treatment failures had oc-
curred during which all patients still participat-
ing in the trial were required to report for the 
final clinic visit). The maximum duration of 
treatment was 80 weeks or until the 138th treat-
ment failure occurred. The primary efficacy end 
point was the time to treatment failure at or after 
week 6. At week 6, patients were considered to 
have treatment failure if they met any one of the 
following criteria in at least one eye: new in-
flammatory lesions relative to baseline, anterior 
chamber cell or vitreous haze grade that did not 
decrease to 0.5+ or lower, or worsening of best 
corrected visual acuity by 15 or more letters 
on the Early Treatment Diabetic Retinopathy 
Study chart, relative to the best state previously 
achieved. After week 6, patients were considered 
to have treatment failure if they had new active, 
inflammatory lesions relative to baseline, a two-
step increase in anterior chamber cell or vitreous 
haze grade, or a worsening of best corrected 
visual acuity by 15 or more letters on the Early 
Treatment Diabetic Retinopathy Study chart, 
relative to the best state previously achieved, in 
at least one eye.
Nine ranked secondary end points related to 
disease state were tested for significance in the 
comparison between the adalimumab group and 
the placebo group in the following hierarchical 
order (from first to last): change in anterior 
chamber cell grade in each eye, change in vitreous 
haze grade in each eye, change in best corrected 
visual acuity (logarithm of the minimum angle 
of resolution) in each eye, time to optical coher-
ence tomographic (OCT) evidence of macular 
edema in at least one eye, percent change in cen-
tral retinal thickness in each eye, change in NEI 
Visual Functioning Questionnaire–25 (VFQ-25) 
composite score, change in VFQ-25 distance vi-
sion subscore, change in VFQ-25 near vision sub-
score, and change in VFQ-25 ocular pain subscore. 
All ranked secondary end points, with the excep-
tion of the time to OCT evidence of macular 
edema in at least one eye, were analyzed by a 
comparison of the best state achieved before 
week 6 with the value at the final study visit.
All patients who received at least one dose of 
adalimumab or placebo were included in the 
safety analysis. Adverse events were monitored 
and reported from the time the first dose of 
adalimumab or placebo was administered until 
70 days after the last dose was administered or 
until patients were moved into a separate exten-
sion study. Data on serious adverse events were 
collected starting from the time of informed 
consent. Adverse events were tabulated with the 
use of system organ classes and preferred terms 
from the Medical Dictionary for Regulatory 
Activities, version 17.0. The immunogenicity of 
adalimumab was evaluated at baseline and at 
weeks 12, 27, 36, and 52, or at the termination 
visit for patients who discontinued treatment 
before week 52.
Procedures
The schedule of trial procedures is available in 
Table S3 in the Supplementary Appendix. The 
presence or absence of inflammatory chorioreti-
nal or retinal vascular lesions was determined by 
dilated indirect ophthalmoscopy. Anterior cham-
ber cell counts were assessed by slit-lamp bio-
microscopy and were graded according to Stan-
dardization of Uveitis Nomenclature Working 
Group criteria.20 Vitreous haze was assessed by 
means of dilated indirect ophthalmoscopy and 
was graded with the use of Standardization of 
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Uveitis Nomenclature Working Group–adapted 
NEI criteria.20,21 The determination of whether 
macular edema was present was based on the 
OCT-measured thickness of the macula (mea-
sured with a Stratus OCT [Carl Zeiss Meditec], 
Cirrus HD-OCT [Carl Zeiss Meditec], or Spectralis 
[Heidelberg Engineering] system).
Statistical Analysis
Efficacy end points were analyzed in the inten-
tion-to-treat data set. For all patients, the time 
to treatment failure (the primary end point) and 
the time to OCT evidence of macular edema (a 
secondary end point) were based on the first 
eye to meet the criteria for treatment failure or 
macular edema; the change in anterior chamber 
cell grade in each eye, change in vitreous haze 
grade in each eye, change in best corrected vi-
sual acuity (logarithm of the minimum angle of 
resolution) in each eye, and percent change in 
central retinal thickness in each eye were ana-
lyzed with the use of data from each eye individu-
ally. The time to treatment failure was compared 
between the study groups with a log-rank test. 
A proportional-hazards model with study group 
as a factor was fitted to estimate the hazard 
ratio with its 95% confidence interval. The time 
to treatment failure due to each component of 
the primary end point and the time to macular 
edema were analyzed in the same way. Other 
ranked secondary end points were evaluated by 
analysis of variance. The analysis of variance 
was adjusted for clustered observations because 
data from both individual eyes were included. 
Testing of ranked secondary end points was 
conducted in hierarchical order. In the case of a 
nonsignificant test result, the confirmatory multi-
ple-testing procedure was stopped, and P values 
for secondary end points further down in the 
hierarchy were considered to be exploratory and 
descriptive in nature. We also performed explor-
atory analyses of the results to determine whether 
there was an association between the efficacy of 
adalimumab and the underlying condition caus-
ing uveitis or the status of baseline immuno-
modulatory therapy.
Patient information was summarized descrip-
tively, continuous variables were compared by 
analysis of variance, and discrete variables were 
analyzed with the use of chi-square tests. Adverse 
events that occurred during treatment were 
summarized descriptively and were tabulated as 
events per 100 patient-years to avoid confound-
ing by between-group differences in the duration 
of exposure to adalimumab or placebo. All sta-
tistical tests were two-sided, and P values of less 
than 0.05 were considered to indicate statistical 
significance. Analyses were performed by the 
trial sponsor with SAS software, version 9.2 (SAS 
Institute). The data reported here reflect the final 
trial data.
Because the inclusion of eyes with macular 
holes or retinal detachment could confound the 
measurement of uveitic macular edema and cen-
tral retinal thickness, a post hoc analysis of two 
secondary end points (time to OCT evidence of 
macular edema and percent change in central 
retinal thickness) was performed that excluded 
patients with these conditions. For these analy-
ses, OCT-determined thickness values were used 
to quantify new macular edema.
R esult s
Patients
Of the 223 patients who were randomly assigned 
to a study group, 217 were included in the inten-
tion-to-treat analyses (110 in the adalimumab 
group and 107 in the placebo group); 6 patients 
were excluded because of a lack of compliance 
with Good Clinical Practice guidelines at the 
study site. The enrollment of patients started on 
August 10, 2010, and was completed on August 
29, 2014. Most patients were female (57%) and 
white (80%), and 45% of patients had a diagnosis 
of panuveitis. The mean age of the patients was 
42.7 years, and the mean duration of uveitis was 
46 months. There were no significant between-
group differences in demographic or baseline 
characteristics (Table 1). The duration of expo-
sure to topical glucocorticoids before discontin-
uation of this therapy (at approximately week 9) 
was similar in the two groups (Table S4 in the 
Supplementary Appendix). A total of 18 patients 
who received adalimumab and 7 patients who 
received placebo discontinued participation in the 
trial; in both groups, adverse events were the 
most common cause of discontinuation (Fig. S1 
in the Supplementary Appendix).
Efficacy
The median time to treatment failure was 24 
weeks in the adalimumab group and 13 weeks 
in the placebo group; there was early and sus-
tained separation of the treatment-failure curves 
(Fig. 1A). Patients who received adalimumab 
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Characteristic
Placebo Group 
(N = 107)
Adalimumab Group 
(N = 110) P Value
Age — yr† 0.97
Mean 42.6±14.2 42.7±15.6
Range 18–79 18–81
Race — no. (%)‡§
White 86 (80) 88 (80) 0.95
Black 12 (11) 11 (10)
Asian 2 (2) 4 (4)
Other 7 (7) 7 (6)
Type of uveitis — no. (%)§ 0.96
Panuveitis 47 (44) 50 (45)
Posterior uveitis 37 (35) 36 (33)
Intermediate uveitis 23 (21) 24 (22)
Diagnosis — no. (%) NT
Idiopathic uveitis 45 (42) 36 (33)
Birdshot choroidopathy 20 (19) 24 (22)
Vogt–Koyanagi–Harada disease 14 (13) 11 (10)
Sarcoidosis 8 (7) 10 (9)
Behçet’s disease 4 (4) 12 (11)
Multifocal choroiditis and panuveitis 3 (3) 8 (7)
Other 13 (12) 9 (8)
Duration of uveitis — mo† 0.20
Mean 51.0±72.2 40.2±51.2
Range 1.2–554.9 1.5–305.9
No. of flares in the past 12 mo — no. (%)§ 0.66
1 19 (18) 18 (16)
2 46 (43) 54 (49)
≥3 42 (39) 38 (35)
Concomitant immunomodulatory treatment — no. (%) NT
Azathioprine 4 (4) 4 (4)
Cyclosporine 3 (3) 10 (9)
Methotrexate 12 (11) 9 (8)
Mycophenolate mofetil or equivalent 14 (13) 11 (10)
Affected eye — no. (%)§ 0.46
Both 99 (93) 98 (89)
Left only 5 (5) 5 (5)
Right only 3 (3) 7 (6)
*  Plus–minus values are means ±SD. NT denotes not tested.
†  P value for between­group difference was based on a one­way analysis of variance.
‡  Race was self­reported.
§  P value for between­group difference was based on a chi­square or Fisher’s exact test.
Table 1. Demographic and Baseline Clinical Characteristics of Patients in the Intention-to-Treat Population.*
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were significantly less likely than those who re-
ceived placebo to have treatment failure (hazard 
ratio, 0.50; 95% confidence interval [CI], 0.36 to 
0.70; P<0.001). Patients who received adalimu-
mab had a significantly lower risk of treatment 
failure caused by vitreous haze (hazard ratio, 
0.32; 95% CI, 0.18 to 0.58; P<0.001), new active 
inflammatory lesions (hazard ratio, 0.38; 95% 
CI, 0.21 to 0.69; P = 0.001), anterior chamber cell 
grade (hazard ratio, 0.51; 95% CI, 0.30 to 0.86; 
P = 0.01), or a worsening of best corrected visual 
acuity (hazard ratio, 0.56; 95% CI, 0.32 to 0.98; 
P = 0.04) (Fig. 1B). Similar results were found in 
subgroup analyses (see the Supplementary Ap-
pendix). There were significantly more reasons 
for treatment failure in the placebo group than 
in the adalimumab group (P = 0.002) (Fig. S2 in 
the Supplementary Appendix). An increase in 
vitreous haze grade was the most frequent rea-
son for treatment failure in the placebo group 
(36%) and the least frequent reason in the ada-
limumab group (15%) (Fig. 2). An increase in 
anterior chamber cell grade was the most fre-
quent reason for treatment failure in the adalim-
umab group (22%); a worsening of best corrected 
visual acuity was the least frequent reason for 
treatment failure in the placebo group (25%).
We performed exploratory analyses of the 
results to determine whether there was an asso-
ciation between the efficacy of adalimumab and 
the type of diagnosis or status of baseline im-
munomodulatory therapy. Diagnosis-defined sub-
groups with 20 or more patients per study group 
were analyzed. Only two subgroups — idio-
pathic uveitis and birdshot choroidopathy — met 
this criterion. We found that the efficacy of 
adalimumab was significantly greater than that 
of placebo among patients who had a diagnosis 
of idiopathic uveitis (hazard ratio, 0.50; 95% CI, 
0.31 to 0.80; P = 0.003) but not among patients 
with birdshot choroidopathy (hazard ratio, 0.49; 
95% CI, 0.21 to 1.14; P = 0.09). We also found the 
efficacy of adalimumab to be significantly great-
er than that of placebo in the subgroup of pa-
tients who were not using immunomodulatory 
therapies at baseline (hazard ratio, 0.49; 95% CI, 
0.33 to 0.73; P<0.001) but not among patients 
who were using immunomodulatory therapies at 
baseline (hazard ratio, 0.55; 95% CI, 0.30 to 1.01; 
P = 0.05). Given the small number of patients in 
each subgroup and the exploratory nature of 
these analyses, the results must be considered as 
tentative.
Hierarchical testing of the ranked secondary 
outcomes showed that worsening of anterior 
chamber cell grade, worsening of vitreous haze 
grade, and worsening of best corrected visual 
acuity were significantly less common among 
patients who received adalimumab than among 
those who received placebo (P≤0.01 for all three 
end points). The difference between the groups 
in the time to OCT evidence of macular edema 
was not significant (Table 2); therefore, no fur-
ther confirmatory statistical testing of second-
ary end points was performed. An exploratory 
post hoc analysis showed that, among patients 
with no macular edema, macular holes, or reti-
nal detachment at baseline, the risk of develop-
ment of new macular edema defined by retinal 
thickening was 67% lower with adalimumab than 
with placebo (P = 0.02). Exploratory analyses of 
the percent change in central retinal thickness 
in each eye, the change in VFQ-25 composite 
score, the change in VFQ-25 distance vision sub-
score, the change in VFQ-25 near vision subscore, 
and the change in VFQ-25 ocular pain subscore, 
which were performed for hypothesis-generating 
purposes, showed that the results favored ada-
limumab for each outcome with the exception of 
the change in VFQ-25 distance vision subscore 
(Table S5 in the Supplementary Appendix).
Safety
The incidence of adverse events was 971.7 per 100 
person-years in the placebo group (430 events), 
and 1052.4 per 100 person-years in the adalimu-
mab group (657 events) (Table 3). The potential 
relationship of adverse events to the trial inter-
vention (adalimumab or placebo) was judged 
while investigators were unaware of the study-
group assignments. Among the adverse events 
reported, 124.3 per 100 person-years (55 events) 
in the placebo group and 257.9 per 100 person-
years (161 events) in the adalimumab group were 
judged by investigators to have been possibly 
related to the trial intervention. Serious adverse 
events were more common in the adalimumab 
group; the incidence was 28.8 per 100 person-
years (18 events) in the adalimumab group and 
13.6 per 100 person-years (6 events) in the place-
bo group (Table 3); of these, 9.6 per 100 person-
years (6 events) in the adalimumab group and 
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Figure 1. Kaplan–Meier Curves of the Rate of Treatment Failure.
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6.8 per 100 person-years (3 events) in the pla-
cebo group were judged by investigators to have 
been possibly related to the trial intervention. The 
most frequently reported adverse events were 
injection-site reactions and allergic reactions. 
Serious infections occurred at a similar rate in 
the two groups. Two cancers (carcinoid tumor of 
the gastrointestinal tract and glioblastoma multi-
forme) and 1 event each of active tuberculosis, 
latent tuberculosis, lupus or lupuslike reaction, 
and demyelinating disorder were reported in the 
adalimumab group.
Adverse events leading to discontinuation of 
participation in the trial were more common in 
the adalimumab group and included choroidal 
neovascularization, blurred vision, reduced visual 
acuity, fatigue, malaise, and suicidal ideation. 
We detected anti-adalimumab antibodies in 3 of 
110 patients in the adalimumab group (2.7%) 
during the trial. The 3 patients in whom anti-
adalimumab antibodies were detected had treat-
ment failure at 16, 44, and 48 weeks; the median 
time to treatment failure among the 107 patients 
in whom anti-adalimumab antibodies were not 
detected was 24 weeks.
Figure 2. Reasons for Treatment Failure in Each Study Group.
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Ranked Secondary Variable
Placebo Group 
(N = 107)
Adalimumab Group 
(N = 110)
Mean Between-Group 
Difference (95% CI) P Value
No. of 
Patients Value*
No. of 
Patients Value*
Mean change in anterior chamber cell grade† –0.29 (–0.51 to –0.07) 0.01‡
Left eye 102 0.59 101 0.35
Right eye 102 0.69 101 0.36
Mean change in vitreous haze grade§ –0.27 (–0.43 to –0.11) <0.001‡
Left eye 103 0.33 101 0.11
Right eye 103 0.45 101 0.13
Mean change in best corrected visual acuity — log­
arithm of the minimum angle of resolution
–0.07 (–0.11 to –0.02) 0.003‡
Left eye 103 0.12 101 0.07
Right eye 103 0.13 101 0.04
Median time to OCT evidence of cystoid macular 
edema on or after week 6 — mo¶
45 6.2 55 11.1 0.23
*  With the exception of the time to optical coherence tomographic (OCT) evidence of macular edema, data reflect the change from the best 
state achieved before week 6 to the state at the final or early termination visit.
†  Anterior chamber cell grades range from 0 to 4+, with higher scores indicating more cells visible in the anterior chamber and greater severity 
of uveitis.
‡  The P value for the between­group difference was calculated by analysis of variance, with treatment as a factor, and was adjusted for clus­
tered observations.
§  Vitreous haze grades range from 0 to 4+, with higher scores indicating greater severity of uveitis.
¶  Cystoid macular edema was included only for patients who did not have cystoid macular edema at baseline. The P value for the between­
group comparison was calculated by log­rank test. The hazard ratio for development of macular edema on or after week 6 in the adalimumab 
group, as compared with the placebo group, was 0.70 (95% CI, 0.39 to 1.26).
Table 2. Ranked Secondary Efficacy Variables in the Intention-to-Treat Population.
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Adverse Event
Placebo Group 
(N = 112)
Adalimumab Group 
(N = 111)
no. of events
events/100 
patient-years no. of events
events/100 
patient-years
Any adverse event 430 971.7 657 1052.4
Adverse event leading to death 0 0 1† 1.6
Serious adverse event 6 13.6 18 28.8
Accidental overdose 0 0 1 1.6
Anaphylactic reaction 0 0 1 1.6
Angle­closure glaucoma 0 0 1 1.6
Carcinoid tumor of the gastrointestinal tract 0 0 1 1.6
Chronic renal failure 0 0 1 1.6
Demyelination 0 0 1 1.6
Fluid overload 0 0 1 1.6
Glioblastoma multiforme 0 0 1 1.6
Ligament rupture 0 0 1 1.6
Lupuslike syndrome 0 0 1 1.6
Neovascularization 0 0 1 1.6
Pilonidal cyst 0 0 1 1.6
Pneumonia 0 0 1 1.6
Tendon rupture 0 0 1 1.6
Tuberculosis 0 0 1 1.6
Upper respiratory tract infection 0 0 1 1.6
Urinary tract infection 0 0 1 1.6
Urticaria 0 0 1 1.6
Abortion induced 1 2.3 0 0
Acute hepatitis 1 2.3 0 0
Acute pyelonephritis 1 2.3 0 0
Sepsis 1 2.3 0 0
Viral gastroenteritis 1 2.3 0 0
Wrist fracture 1 2.3 0 0
Adverse event leading to discontinuation of the 
trial intervention
5 11.3 13 20.8
Adverse event possibly related to the trial inter­
vention‡
55 124.3 161 257.9
Serious adverse event possibly related to the trial 
intervention‡
3 6.8 6 9.6
Injection­site reaction 7 15.8 28 44.9
Allergic reactions 6 13.6 14 22.4
Treatment­related allergic reaction 1 2.3 4 6.4
Serious infection 3 6.8 5 8.0
Opportunistic infection (excluding oral candidia­
sis and tuberculosis)
0 0 0 0
Cancer§ 0 0 2 3.2
Active tuberculosis 0 0 1 1.6
Latent tuberculosis 0 0 1 1.6
Table 3. Adverse Events in the Safety Population.*
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Discussion
In this trial involving patients with active, vision-
threatening, noninfectious intermediate or pos-
terior uveitis or panuveitis, treatment with adali-
mumab was associated with a significantly 
lower risk of treatment failure than was placebo; 
there was an early and sustained separation of 
adalimumab and placebo treatment-failure curves 
regardless of whether patients were receiving 
nonadalimumab immunomodulatory treatment 
at baseline. Without glucocorticoid support, 
adalimumab treatment controlled multiple as-
pects of uveitic inflammation and was associat-
ed with a lower risk of uveitic flare and a longer 
time to a flare than was placebo.
Posterior manifestations of uveitis, such as 
vitreous haze and retinal lesions, are more close-
ly associated with vision loss than is anterior 
inflammation (as indicated, for example, by the 
number of anterior chamber cells).22 Vitreous 
haze was the most common reason for treat-
ment failure in the placebo group and was the 
least common cause of treatment failure in the 
adalimumab group; patients who received adali-
mumab were approximately one third as likely to 
have treatment failure caused by a worsening 
grade of vitreous haze. Treatment failure due to 
newly active chorioretinal lesions was also more 
common with placebo than with adalimumab. 
These observations are consistent with an effect 
of adalimumab on posterior segment inflamma-
tion. Clinically relevant outcomes associated with 
uveitic inflammation (e.g., grades of anterior 
chamber cells and vitreous haze, best corrected 
visual acuity, and central retinal thickness) were 
significantly better with adalimumab than with 
placebo.
The efficacy results of this controlled trial are 
supported by the results of previous uncon-
trolled studies. In a prospective, multicenter, 
open-label trial of adalimumab involving patients 
with refractory noninfectious uveitis, 68% of the 
patients met prespecified criteria for clinical 
success after 10 weeks of treatment.17 In a retro-
spective case series of patients with chronic 
noninfectious uveitis, sustained inflammation 
control and glucocorticoid sparing were achieved 
in 38% of the patients after 12 weeks and in 
57% of the patients after 1 year.23 In a prospec-
tive study involving 131 patients with refractory 
noninfectious uveitis, nearly half of whom had 
panuveitis and 31% of whom had cystoid macu-
lar edema at baseline, adalimumab treatment 
was associated with a significant reduction in 
macular thickness relative to baseline and with 
resolution of macular edema.15 Likewise, in a 
retrospective, multicenter study involving 60 pa-
tients with active noninfectious uveitis, adalim-
umab reduced macular edema in 53% of the 32 
patients who had had macular edema before 
treatment; visual acuity and anterior chamber 
cells were also improved.16
The low immunogenicity of adalimumab that 
was observed in our trial was within the range of 
rates observed with adalimumab in other disease 
states.12 No new safety signals were detected.13,24 
The overall rate of adalimumab-associated ad-
verse events exceeded that of placebo-associated 
adverse events, as did the rate of adalimumab-
Adverse Event
Placebo Group 
(N = 112)
Adalimumab Group 
(N = 111)
no. of events
events/100 
patient-years no. of events
events/100 
patient-years
Lupus or lupuslike reaction 0 0 1 1.6
Demyelinating disorder 0 0 1 1.6
*  The total numbers of patient­years were 44.3 in the placebo group and 62.4 in the adalimumab group.
†  The death was due to end­stage chronic renal disease and occurred on day 37 (post­treatment day 3); it was judged by 
the investigators not to be related to the trial intervention.
‡  The assessment of whether an event was related to the trial intervention was made by the investigator. The investigator 
was unaware of the study­group assignment at the time of the assessment.
§  The two cases of cancer included one carcinoid tumor of the gastrointestinal tract (detected on day 244 and surgically 
removed and reported as resolved on day 251; adalimumab treatment was not interrupted) and one case of glioblasto­
ma multiforme (detected on day 242; adalimumab was discontinued because of this event; the last adalimumab dose 
was administered on day 248).
Table 3. (Continued.)
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associated serious adverse events and adverse 
events leading to discontinuation of treatment, 
possibly because of the immunomodulatory 
 action of the drug. This notion is supported 
by the greater frequency of respiratory tract 
infections (e.g., nasopharyngitis and bronchi-
tis) related to adalimumab, as assessed by in-
vestigators, and of adalimumab-related adverse 
events, such as infections and allergic reac-
tions, leading to discontinuation; these adverse 
events have been described previously.12 All 
serious adverse events were unique, and no pat-
tern was identified among the adverse events 
that led to the discontinuation of adalimumab 
treatment.
Randomized, controlled trials of immuno-
suppressive therapies for noninfectious uveitis 
are generally lacking. The design, large patient 
population, diversity of uveitis diagnoses, four-
component primary end point, and hierarchical 
statistical analysis of secondary end points were 
strengths of our trial. The composite primary 
end point assessed multiple facets of the disease, 
spanning from anterior to posterior segments of 
the eye, and enabled broader assessment of the 
response to treatment.
The extent to which we can interpret the trial 
data is limited. In patients receiving adalimu-
mab, the time to treatment failure may have been 
underestimated and rates of treatment failure 
may have been overestimated, as compared with 
these measures in a nontrial setting, because all 
the patients rapidly discontinued glucocorticoid 
treatment. In clinical practice, patients receive 
oral or topical glucocorticoids as needed to main-
tain control of their uveitis.5 Regardless, because 
more than half the patients had treatment fail-
ure by 80 weeks, adalimumab delayed uveitic 
flares in the majority of eyes but, as expected, 
did not “cure” the patients’ uveitis.
Treatment with adalimumab effectively achieved 
early and sustained disease control after discon-
tinuation of glucocorticoid treatment by both 
markedly reducing inflammation and decreasing 
visual impairment in patients with active non-
infectious intermediate uveitis, posterior uveitis, 
or panuveitis. There were more treatment-related 
adverse events and more serious adverse events 
in the adalimumab group than in the placebo 
group in the trial. Adalimumab reduced the 
worsening of several clinically relevant inflam-
matory measures and significantly lowered the 
risk of uveitic flare or visual impairment.
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